A Phase 1 clinical trial testing azercabtagene zapreleucel (azer-cel), TG Therapeutics’ CAR-T-cell therapy, in progressive forms of multiple sclerosis (MS) is now recruiting participants at eight sites across the U.S. The study (NCT06680037) is expected to enroll up to 32 adults with primary progressive MS…